Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs

Pharmacogenetics and Genomics

Volumn 22, Issue 11, 2012, Pages 784-795

  Urban, Thomas J ^a   Shen, Yufeng ^h   Stolz, Andrew ^f   Chalasani, Naga ^j   Fontana, Robert J ^k   Rochon, James ^a   Ge, Dongliang ^a   Shianna, Kevin V ^a   Daly, Ann K ^p   Lucena, M Isabel ^s   Nelson, Matthew R ^b   Molokhia, Mariam ^q   Aithal, Guruprasad P ^r   Floratos, Aris ^h   Pe'Er, Itsik ⁱ   Serrano, Jose ^l   Bonkovsky, Herbert ^c,d   Davern, Timothy J ^g   Lee, William M ^m   Navarro, Victor J ⁿ   Talwalkar, Jayant A ^o   Goldstein, David B ^a   Watkins, Paul B ^d,e   more..

^a DUKE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Hamner University of North Carolina   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ Columbia University ^*  (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^m UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁿ THOMAS JEFFERSON UNIVERSITY   (United States)

^o MAYO CLINIC   (United States)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q KING'S COLLEGE LONDON   (United Kingdom)

^r NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^s HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

more..

Author keywords

drug induced liver injury; genome wide association study; pharmacogenetics

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; FLUCLOXACILLIN; STAT4 PROTEIN;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE REGISTRY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE SYSTEM; LATENT PERIOD; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS;

EID: 84867578409     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283589a76     Document Type: Article

References (29)

1. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947-954.
2. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48:1680-1689.
3. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10:1467-1487.
4. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010; 11:607-611.
5. Lucena MI, Kaplowitz N, Hallal H, Castiella A, Garcia-Bengoechea M, Otazua P, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry. The dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011.
6. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32:55-68.
7. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe er I, Floratos A, et al. HLAB* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-819.
8. Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 2006; 7:633-638.
9. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-521.
10. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011.
11. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
12. Nelson MR, Bryc K, King KS, Indap A, Boyko AR, Novembre J, et al. The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am J Hum Genet 2008; 83:347-358.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
14. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
16. Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, et al. WGAViewer: software for genomic annotation of whole genome association studies. Genome Res 2008; 18:640-643.
17. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37:84-89.
18. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106:9362-9367.
19. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for casecontrol genetic association analyses. BMC Genet 2008; 9:36.
20. Edwards BJ, Haynes C, Levenstien MA, Finch SJ, Gordon D. Power and sample size calculations in the presence of phenotype errors for case/ control genetic association studies. BMC Genet 2005; 6:18.
21. Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 2008; 8:398-403.
22. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 2002; 61:7-12.
23. Kaur J, Sanyal SN. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac. Eur J Cancer Prev 2010; 19:319-327.
24. Zieleniak A,Wojcik M,Wozniak LA. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz) 2008; 56:331-345.
25. Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010; 376:1882-1883.
26. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genomewide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42:711-714.
27. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLADQA1* 02:01 Is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29:667-673.
28. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8:186-195.
29. Suzuki A, Yuen N,Walsh J, Papay J, Hunt CM, Diehl AM. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophenassociated liver injury. Clin Gastroenterol Hepatol 2009; 7:882-888.